HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study
Authors' conclusion
Most people receiving second-line glucose-lowering treatment in this global cohort achieved stable good or highly improved long-term glycaemic control. One-fifth of participants showed moderate or poor glycaemic control during follow-up. Further large-scale studies are required to characterize possible factors associated with patterns of glycaemic control to inform personalized diabetes treatment.
Study context
- Population
- People with T2D beginning second-line glucose-lowering therapyassessed after exclusions
- Participants
- 9,295 people
- Exposure
- Stable good vs Stable moderate vs Stable poor vs Highly improved
- Outcome
- Distinct HbA1c trajectories
- Follow-up
- Baseline and 6, 12, 24 and 36 months
Methodological detailsglobal, latent class growth modelling
- Global
- Latent class growth modelling
Main finding
As reported in the abstract
HbA1c trajectory groups (share of participants) · 3 years
Observational data: associations, not effects.
Further findings
Treatment use over time
- Dual oral therapy use decreased over time in all groups, compensated by increasing use of other regimens
- Injectable agent use increased over time in moderate and poor control groups
Factors associated with trajectory
- Participants from high-income countries more probable to be in stable good trajectory (logistic regression)
Original publication
HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study. Diabetes Obes Metab. Published 5 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →